Andreas Mueller
Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland
Zeljkovic I, Normand C, Linde C, Dickstein K, Delacretaz E, Auricchio A, Mueller A, Ammann P, Breitenstein A, Burri H, Sticherling C. Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. Swiss Med Wkly 2018; 148:w14643.
Aug 22, 2018Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland
Aug 22, 2018Swiss Med Wkly 2018; 148:w14643
Zeljkovic Ivan, Normand Camilla, Linde Cecilia, Dickstein Kenneth, Delacretaz Etienne, Auricchio Angelo, Mueller Andreas, Ammann Peter, Breitenstein Alexander, Burri Haran, Sticherling Christian
Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation
Conen D, Sticherling C, Bonati L, Ehret G, Roten L, Fischer U, Monsch A, Stippich C, Wuerfel J, Schwenkglenks M, Kuehne M, Erne P, Di Valentino M, Novak J, Rodondi N, Mueller A, Beer J, Auricchio A, Ammann P, Hayoz D, Kobza R, Moschovitis G, Shah D, Schlaepfer J, Osswald S. Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Med Wkly 2017; 147:w14467.
Jul 11, 2017Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation
Jul 11, 2017Swiss Med Wkly 2017; 147:w14467
Conen David, Sticherling Christian, Bonati Leo, Ehret Georg, Roten Laurent, Fischer Urs, Monsch Andreas, Stippich Christoph, Wuerfel Jens, Schwenkglenks Matthias, Kuehne Michael, Erne Paul, Di Valentino Marcello, Novak Jan, Rodondi Nicolas, Mueller Andreas, Beer Juerg, Auricchio Angelo, Ammann Peter, Hayoz Daniel, Kobza Richard, Moschovitis Giorgio, Shah Dipen, Schlaepfer Juerg, Osswald Stefan
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer 2017; 17:265.
Apr 13, 2017Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Apr 13, 2017BMC cancer 2017; 17:265
Pestalozzi Bernhard C, Novak Urban, Nussbaum Catrina Uhlmann, Seifert Bettina, Bigler Martin, Bize Vincent, Vilei Simona Berardi, Rageth Christoph, Aebi Stefan, Borner Markus, Buser Katharina, Tausch Christoph, Dedes Konstantin J, Rochlitz Christoph, Zimmermann Stefan, von Moos Roger, Winterhalder Ralph, Ruhstaller Thomas, Mueller Andreas
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Zaman K, Rondeau S, Hawle H, Rudolf C, Perey L, Wiliders H, Berset C, Mueller A, Rochlitz C, Hasler-Strub U, Mamot C, Winterhalder R, Neven P. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 2015; 51:1212-20.
Apr 16, 2015Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Apr 16, 2015Eur J Cancer 2015; 51:1212-20
Zaman Khalil, Rondeau Stephanie, Hawle Hanne, Rudolf Christine Biaggi, Perey Lucien, Wiliders Hans, Berset Catherine, Mueller Andreas, Rochlitz Christoph, Hasler-Strub Ursula, Mamot Christoph, Winterhalder Ralph, Neven Patrick
Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
Ruhstaller T, Mueller A, Koeberle D, Thuerlimann B. Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:8547-8.
Nov 20, 2005Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
Nov 20, 2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:8547-8
Ruhstaller Thomas, Mueller Andreas, Koeberle Dieter, Thuerlimann Beat